Neurelis, Inc.
Injectable seizure rescue medications (NAYZILAM®, diazepam formulations)
New patent ·
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2007
- Latest Form D
- $115M, Mar 2021
- Total capital
- $190M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $190M
- 8 Form D · last Mar 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 29 pending · first 2017
- Rank in peer group#167 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$115M
- Private capital raisedForm D · SEC · 7th filing$15.3M
- Private capital raisedForm D · SEC · 6th filing$40.5M
- Private capital raisedForm D · SEC · 5th filing$5.2M
- Private capital raisedForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$1.5M
- Private capital raisedForm D · SEC · 2nd filing$1.1M
- Private capital raisedForm D · SEC · 1st filing$1.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#167 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Cam C. GarnerDirectorNamed in SEC Form D filings
- Craig C. ChamblissExecutive Officer, DirectorNamed in SEC Form D filings
- David A. GonyerDirectorNamed in SEC Form D filings
- David F. HaleDirectorNamed in SEC Form D filings
- George F. StuartExecutive OfficerNamed in SEC Form D filings
- Huaizheng C. PengDirectorNamed in SEC Form D filings
Show all 11 people
- Kevin C. LiDirectorNamed in SEC Form D filings
- Priyanka F. BelawatDirectorNamed in SEC Form D filings
- Stephen F. CarttDirectorNamed in SEC Form D filings
- William R. LaRueDirectorNamed in SEC Form D filings
- Yong L. ZhangDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 39- New patentAdministration Of Benzodiazepine CompositionsUSPTOUS 12,758,561
- GrantedMethods And Compositions For Treating Seizure Disorders In Pediatric PatientsUSPTOUS 12,599,611
- GrantedAdministration Of Benzodiazepine CompositionsUSPTOUS 12,521,400
Show all 39 patent records
- Administration Of Benzodiazepine CompositionsOct 13, 2026 · US 12,758,561Granted
- Methods And Compositions For Treating Seizure Disorders In Pediatric PatientsApr 14, 2026 · US 12,599,611Granted
- Administration Of Benzodiazepine CompositionsJan 13, 2026 · US 12,521,400Granted
- Intranasal Olanzapine Formulations And Methods Of Their UseNov 20, 2025 · Application 19025895Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseOct 2, 2025 · Application 18946529Pending
- Administration Of Benzodiazepine CompositionsSep 11, 2025 · Application 19219706Pending
- Treatment Of Cavernous Angiomas With A 4-SUBSTITUTED Piperidine DerivativeSep 11, 2025 · Application 19073695Pending
- Administration Of Benzodiazepine CompositionsJun 24, 2025 · US 12,337,061Granted
- Administration Of Benzodiazepine CompositionsJun 10, 2025 · US 12,324,852Granted
- Administration Of Benzodiazepine CompositionsApr 8, 2025 · US 12,268,664Granted
- Intranasal Olanzapine Formulations And Methods Of Their UseDec 24, 2024 · US 12,171,868Granted
- Methods And Compositions For Rapid Delivery Of Anti-seizure TherapeuticsSep 12, 2024 · Application 18405628Pending
- Polymorphs Of Substituted Isoquinoline-based Rho Kinase InhibitorsDec 14, 2023 · Application 18332476Pending
- Administration Of Benzodiazepine CompositionsOct 24, 2023 · US 11,793,786Granted
- Administration Of Benzodiazepine CompositionsApr 6, 2023 · Application 18062062Pending
- Methods And Compositions For Rapid Delivery Of Anti-seizure TherapeuticsJul 14, 2022 · Application 17570535Pending
- Administration Of Benzodiazepine CompositionsFeb 8, 2022 · US 11,241,414Granted
- Administration Of Benzodiazepine CompositionsAug 23, 2018 · Application 15955397Pending
- Administration Of Benzodiazepine CompositionsSep 19, 2017 · US 9,763,876Granted
- Administration Of Benzodiazepine CompositionsJul 13, 2017 · Application 15470498Pending
- Methods And Compositions For Increasing Interseizure Cluster Interval DurationApplication 63284033Pending
- Methods And Compositions For Rapid Delivery Of Anti-seizure TherapeuticsApplication 63276760Pending
- Compositions And Methods For Single Dose Anti-seizure TherapeuticsApplication 63276761Pending
- Methods And Compositions For Treating Seizure Disorders In Pediatric PatientsApplication 63209092Pending
- Methods And Compositions For Rapid Delivery Of Anti-seizure TherapeuticsApplication 63135291Pending
- Oral Film For Rapid Active DeliveryApplication 19621602Pending
- Treatment Of Cavernous Angiomas With A 4-SUBSTITUTED Piperidine DerivativeApplication PCTUS2025018926Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseApplication PCTUS2025011924Pending
- Treatment Of Cavernous Angiomas With A 4-SUBSTITUTED Piperidine DerivativeApplication 63634704Pending
- Treatment Of Cavernous Angiomas With A 4-SUBSTITUTED Piperidine DerivativeApplication 63562607Pending
- Oral Film For Rapid Active DeliveryApplication 63562057Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseApplication 63562060Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseApplication 63621378Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseApplication PCTUS2023016204Pending
- Methods And Compositions For Treating Seizure Disorders In Pediatric PatientsApplication PCTUS2022032951Pending
- Polymorphs Of Substituted Isoquinoline-based Rho Kinase InhibitorsApplication 63350936Pending
- Oral Film For Rapid Active DeliveryApplication PCTUS2025018737Pending
- Intranasal Olanzapine Formulations And Methods Of Their UseApplication 63323592Pending
- Methods And Compositions For Rapid Delivery Of Anti-seizure TherapeuticsApplication PCTUS2022011538Pending
Related companies, and why
- Acomhal Research, Inc.Similar federal contract value in Biotech · null in contracts
- ZUCHEM INC.Similar federal contract value in Biotech · null in contracts
- Deepcell, Inc.Similar federal contract value in Biotech · null in contracts
- Coeptis Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Willow Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Validus Cellular Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .